This document summarizes key findings from an atlas of variation in healthcare for people with liver disease in England. It finds significant variations in outcomes like emergency admissions, chronic liver disease mortality, and liver cancer mortality across different localities. It also identifies variations in processes of care like rates of transplantation, hepatitis C testing, obesity rates, and use of day-case surgery. The variations are likely due to differences in risk factors, service configuration, and adherence to clinical guidance across areas. Addressing unwarranted variations could improve outcomes and reduce costs for people with liver disease.
Professor Sue Hill OBE, Chief Scientific Officer for Englandrightcare
We are excited to introduce the NHS Atlas of Variation in Diagnostic Services, the latest publication in the series of impressive NHS Atlases, which have highlighted variation in the provision of healthcare services.
Diagnostic services are of great importance in the NHS because, when used correctly, they support or rule out potential diagnoses, and underpin the effective and efficient management of patient pathways.
Unwarranted variation in the rates of diagnostic testing is of the utmost relevance to individual patients with the over-use, as well as under-use, of diagnostic tests being potentially serious issues. For example, effective capacity planning in imaging services should enable improved patient access balanced against the need to avoid over-use of interventions that have the potential to cause harm, such as ionising radiation.
John Appleby, Chief Economist at The King's Fund, looks at the good, the bad and the inexplicable of NHS health care variations alongside our new report.
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and a...NHS Improvement
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and asthma clinic - Clare Watson
Medicines Management Pharmacist (NHS Hampshire)
Independent Prescriber (Victoria Practice, Aldershot)
Part of a set of presentations from NHS Improvement event: Better value, better outcomes held on Thursday 21 February 2013,
Guoman Tower Hotel, London
How to deliver quality and value in chronic care:sharing the learning from the respiratory programme
Professor Sue Hill OBE, Chief Scientific Officer for Englandrightcare
We are excited to introduce the NHS Atlas of Variation in Diagnostic Services, the latest publication in the series of impressive NHS Atlases, which have highlighted variation in the provision of healthcare services.
Diagnostic services are of great importance in the NHS because, when used correctly, they support or rule out potential diagnoses, and underpin the effective and efficient management of patient pathways.
Unwarranted variation in the rates of diagnostic testing is of the utmost relevance to individual patients with the over-use, as well as under-use, of diagnostic tests being potentially serious issues. For example, effective capacity planning in imaging services should enable improved patient access balanced against the need to avoid over-use of interventions that have the potential to cause harm, such as ionising radiation.
John Appleby, Chief Economist at The King's Fund, looks at the good, the bad and the inexplicable of NHS health care variations alongside our new report.
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and a...NHS Improvement
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and asthma clinic - Clare Watson
Medicines Management Pharmacist (NHS Hampshire)
Independent Prescriber (Victoria Practice, Aldershot)
Part of a set of presentations from NHS Improvement event: Better value, better outcomes held on Thursday 21 February 2013,
Guoman Tower Hotel, London
How to deliver quality and value in chronic care:sharing the learning from the respiratory programme
Professor Liam Smeeth: Big Data, 30 June 2014Nuffield Trust
In this slideshow, Liam Smeeth, Deputy Director and Head of Department of Non-Communicable Disease Epidemiology of the London School of Hygiene and Tropical Medicine discusses big data, e-health and the Farr Institute.
Liam Smeeth spoke at the Nuffield Trust event: The future of the hospital, in June 2014.
The revised OECD Health Systems Performance Framework: methodological issues ...Sax Institute
The OECD is a leading organization in the international measurement of health system performance. The OECD Expert Group on Health Care Quality Indicators (HCQI) has recently revised its performance framework, identifying core indicators and highlighting new directions. Although improving, the capacity of countries to deliver more accurate standardized indicators still needs to be fostered. A particular aspect that deserves attention is the design, planning and implementation of public performance reporting. Such activity, strictly interrelated to the capacity of the information infrastructure, also depends from cultural, organizational and political conditions that can be differently present at the international level. The applicability of standardized principles and the evidence of improved outcomes due to public reporting systems is still questioned to a large extent. A first international conference on the topic of hospital performance reporting has been organized in Rome, Italy in 2014, followed by a second event held in Seoul, South Korea, in 2015. In his talk, Fabrizio Carinci will present recent developments of OECD projects, including:
• state of the art in the definition of OECD performance indicators
• challenges emerging from OECD R&D studies
• transferability and use of definitions at sub-national and provider level
• applicability for hospital performance benchmarking and geographical variation
• limitations imposed by the legislation on privacy and data protection
• an overarching vision of “essential levels of health information”
Through practical examples drawn from his direct experience as Member of the Bureau of the HCQI and other relevant Boards, Prof. Fabrizio Carinci will discuss the state of the art, the role played by national governments (including Australia), and potential avenues for mutual collaboration.
Niek Klazinga | Performance reporting in OECD countriesSax Institute
Dr Niek Klazinga (Head of the Health Care Quality Indicators Project in the OECD Health Division) spoke with the HARC network in December 2014 about current developments in performance measurement and reporting.
HARC stands for the Hospital Alliance for Research Collaboration. HARC is a collaborative network of researchers, health managers, clinicians and policy makers based in NSW, Australia managed by the Sax Institute.
HARC Forums bring members of the HARC network together to discuss the latest research and analysis about important issues facing our hospitals.
For more information visit saxinstitute.org.au.
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...Sax Institute
This presentation from Nicholas Mays, Professor of Health Policy, Director, Policy Innovation Research Unit, Department of Health Services Research & Policy focuses on the challenges, approaches and evaluation of England's Pioneers.
Sir Muir Gray, Chief Knowledge Officer, NHS intoduces the NHS Atlas of Variation, to show show the NHS are maximising values for populations and individuals.
Don't miss our upcoming webinars. Subscribe today!
Join Alies, a patient partner, and Ambreen, a patient-oriented researcher as they talk about Equity-Mobilizing Partnerships in Community (EMPaCT) a patient partnership model co-designed to center the voices of diverse community members and build capacity for equitable patient-oriented partnerships. In this webinar, Alies and Ambreen describe how they engaged multiple stakeholders including institutional leadership, funding bodies, knowledge users and most importantly, the patient community to identify common goals and intersecting opportunities and channelled them to create clear health-equity oriented pathways to change.
View the YouTube video: https://youtu.be/O2FKVsO0x_E
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Keith Ridge, CBE Chief Pharmaceutical Officer
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Anna Dixon on health policy under the coalition governmentThe King's Fund
Anna Dixon, Director of Policy at The King's Fund, looks at the key health policies introduced by the coalition government and at whether they are likely to be effective in future.
Mike Bewick: Primary care transformation: what for and whyThe King's Fund
Mike Bewick looks at the challenges currently facing primary care in the NHS, including unacceptable variations in care, oversupply and undersupply in the health workforce, and the impact of an ageing population. What would great primary care look like in an ideal world?
Matt Sutton: reduced mortality with hospital Pay for Performance in EnglandThe King's Fund
Matt Sutton, Professor of Health Economics at the University of Manchester, explains what the Pay for Performance scheme is and how it has led to a reduction in mortality in the North West of England.
Professor Liam Smeeth: Big Data, 30 June 2014Nuffield Trust
In this slideshow, Liam Smeeth, Deputy Director and Head of Department of Non-Communicable Disease Epidemiology of the London School of Hygiene and Tropical Medicine discusses big data, e-health and the Farr Institute.
Liam Smeeth spoke at the Nuffield Trust event: The future of the hospital, in June 2014.
The revised OECD Health Systems Performance Framework: methodological issues ...Sax Institute
The OECD is a leading organization in the international measurement of health system performance. The OECD Expert Group on Health Care Quality Indicators (HCQI) has recently revised its performance framework, identifying core indicators and highlighting new directions. Although improving, the capacity of countries to deliver more accurate standardized indicators still needs to be fostered. A particular aspect that deserves attention is the design, planning and implementation of public performance reporting. Such activity, strictly interrelated to the capacity of the information infrastructure, also depends from cultural, organizational and political conditions that can be differently present at the international level. The applicability of standardized principles and the evidence of improved outcomes due to public reporting systems is still questioned to a large extent. A first international conference on the topic of hospital performance reporting has been organized in Rome, Italy in 2014, followed by a second event held in Seoul, South Korea, in 2015. In his talk, Fabrizio Carinci will present recent developments of OECD projects, including:
• state of the art in the definition of OECD performance indicators
• challenges emerging from OECD R&D studies
• transferability and use of definitions at sub-national and provider level
• applicability for hospital performance benchmarking and geographical variation
• limitations imposed by the legislation on privacy and data protection
• an overarching vision of “essential levels of health information”
Through practical examples drawn from his direct experience as Member of the Bureau of the HCQI and other relevant Boards, Prof. Fabrizio Carinci will discuss the state of the art, the role played by national governments (including Australia), and potential avenues for mutual collaboration.
Niek Klazinga | Performance reporting in OECD countriesSax Institute
Dr Niek Klazinga (Head of the Health Care Quality Indicators Project in the OECD Health Division) spoke with the HARC network in December 2014 about current developments in performance measurement and reporting.
HARC stands for the Hospital Alliance for Research Collaboration. HARC is a collaborative network of researchers, health managers, clinicians and policy makers based in NSW, Australia managed by the Sax Institute.
HARC Forums bring members of the HARC network together to discuss the latest research and analysis about important issues facing our hospitals.
For more information visit saxinstitute.org.au.
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...Sax Institute
This presentation from Nicholas Mays, Professor of Health Policy, Director, Policy Innovation Research Unit, Department of Health Services Research & Policy focuses on the challenges, approaches and evaluation of England's Pioneers.
Sir Muir Gray, Chief Knowledge Officer, NHS intoduces the NHS Atlas of Variation, to show show the NHS are maximising values for populations and individuals.
Don't miss our upcoming webinars. Subscribe today!
Join Alies, a patient partner, and Ambreen, a patient-oriented researcher as they talk about Equity-Mobilizing Partnerships in Community (EMPaCT) a patient partnership model co-designed to center the voices of diverse community members and build capacity for equitable patient-oriented partnerships. In this webinar, Alies and Ambreen describe how they engaged multiple stakeholders including institutional leadership, funding bodies, knowledge users and most importantly, the patient community to identify common goals and intersecting opportunities and channelled them to create clear health-equity oriented pathways to change.
View the YouTube video: https://youtu.be/O2FKVsO0x_E
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Keith Ridge, CBE Chief Pharmaceutical Officer
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Anna Dixon on health policy under the coalition governmentThe King's Fund
Anna Dixon, Director of Policy at The King's Fund, looks at the key health policies introduced by the coalition government and at whether they are likely to be effective in future.
Mike Bewick: Primary care transformation: what for and whyThe King's Fund
Mike Bewick looks at the challenges currently facing primary care in the NHS, including unacceptable variations in care, oversupply and undersupply in the health workforce, and the impact of an ageing population. What would great primary care look like in an ideal world?
Matt Sutton: reduced mortality with hospital Pay for Performance in EnglandThe King's Fund
Matt Sutton, Professor of Health Economics at the University of Manchester, explains what the Pay for Performance scheme is and how it has led to a reduction in mortality in the North West of England.
Healthcare Industry India Overview and City ComparisonSanket Baxi
This deck provides an overview of the healthcare delivery sector in India and a comparison between four cities: Ahmedabad, Chennai, Kolkata, Pune. IT covers the size of the sector, the growth rate, the drivers and various healthcare indicators.
Indiana University Health University Hospital Palliative Care ServicesMike Aref
Introduction
In the past three years, Indiana University Health (IUH) University Hospital Palliative Care Services has expanded its size and scope. Our mission remains to treat the suffering of patients with chronic, progressive illnesses, their families, and their providers through symptom optimization and the search for meaning. While continuing to work with patients near the end-of-life and transitioning to hospice we have increasingly been involved with complex patients whose deaths are not imminent or even expected.
Our Team
The team has transitioned from a part-time to a full-time physician, a new full-time nurse practitioner, a new position in a nurse clinical coordinator, increased time for out part-time social worker, and continued part-time chaplain.
New Opportunities for Palliative Care
IUH University Hospital sees some of the sickest of the sick including advanced liver failure, advanced pulmonary disease, and transplant patients. Our service has become involved in alleviating suffering in pancreatic, liver, renal, and multivisceral transplant patients. Our expertise in opiates has placed us in a unique position to assist with patients having pain due to opioid-hyperalgesia and narcotic bowel syndrome. In addition we have started seeing more hepatology, oncology, hematology, and pulmonary patients earlier in their disease.
Out-Patient Services
We have expanded our service to now include out-patient, currently by embedding within other clinics at University Hospital including seeing patient in the multidisciplinary oncology clinic, hematology, digestive and liver disease clinic, and surgical out-patient clinic. In the near future we hope to have dedicated clinic space within the geriatrics clinic.
Chronic Liver Disease in pediatric: a case presentation and discussionDr Abdalla M. Gamal
A presentation from a tutorial about an interesting case that came to the Pediatric Department of Sebha Medical Center and was imaged by the Radiology Department.
The tutorial was a joint effort between Dr Zeinab Salem Ali (from Pediatric Department) and me (from Radiology Department). In her slides, Dr Zeinab presented the case history, examination, investigations, differential diagnosis and discussed the clinical presentation, investigations and management for chronic liver diseases in pediatric patients.In my slides, I discussed the definition, etiology, natural history of this condition and explained the role of imaging in its diagnosis.
These are my slides after some modifications. I added an aknowlegement page to illustrate Dr Zeinab effort and to thank Dr Khaled Aljasem from Pediatric Department for his effort in revising the original presentations and the constructive feedback he provided which improved the quality of the presented material. Then I added a summary for the parts Dr Zeinab has presented to make this powerpoint presentation complete.
This presentation was presented by Dr Zeinab Salem (from Pediatric Department) and me in a joint tutorial between Pediatric Department and Radiology Department of Sebha Medical Center.
Death from liver disease : Implications for end of life care in England
22 March 2012
This report presents the latest data on place of death for those with liver disease and shows how this varies with sex, age, region, socioeconomic deprivation and place. It is aimed at commissioners and providers of end of life care, clinicians caring for patients with liver disease, and others concerned with providing quality end of life care for this patient group, including patients themselves and their carers.
Some key findings:
Liver disease causes approximately 2% of all deaths
The number of people who die from liver disease in England is rising (from 9,231 in 2001 to 11,575 in 2009)
More men than women die from liver disease (60% are men, 40% women)
Alcoholic liver disease accounts for well over a third (37%) of liver disease deaths.
Getting to grips with Population Health - 28th Feb 2018James Carter
A set of slides produced by Thames Valley Strategic Clinical Network to support the familiarisation event on Population Health held in Maidenhead on Wednesday 28th February 2018.
With thanks to all colleagues, attendees, chairs and speakers for their involvement on the day.
James Carter - Senior Network Manager TVSCN
james.carter1@nhs.net
Following our successful piece on HIV in Sex Workers, the Lancet asked us to produce an infographic to summarise the findings of the UK Commission on Liver Disease.
Producer: Aimée Stewart • Designers: Paulo Estriga & Caroline Leprovost for Graphic Digital Agency
Epidemiology of Non Communicable Diseases (NCDs)Prabesh Ghimire
Declaration: The materials incorporated in this document have come from variety of sources and compiler bears no responsibilities for any information contained herein. The compiler acknowledges all the sources although references have not been explicitly cited for all the contents in this document.
Dr. Rakesh K. Srivastava
Dr. Rakesh K. Srivastava (Ph.D., FRSM, FRSPH) is the name which has highest value that holds as the professor and scientist. He has the years of the expertise in the field of science and medicine. Dr. Srivastava understands the science in such way that will help the others to know the best.
The need to understand variation in healthcare population healthcare online...rightcare
Variation in healthcare remains endemic, with many articles published in the past 40 years identifying the existence of variations in health care across demographic groups, geographic areas, institutions and even individual health care providers within a single institution and in hospital treatment rates.
There is also evidence of variations in general medical practice and between general practitioners (GPs) and practices, with variations identified in areas such as the frequency of contacts, registration of diagnoses, diagnostic test ordering, referrals, prescription rates, and return visits.
Mapping variations presents some clear directions of travel. For instance, if there is variation
in rates of admission to stroke units, it is obvious that the rate of admission needs to
increase in those populations in which the rate of admission is low. Unwarranted variations
offer health services in every country the opportunity to obtain greater value from
healthcare resources.
Introduction why act - Right Care for Populations - online learningrightcare
Population healthcare focuses primarily on populations defined by a common need which may be a symptom such as breathlessness, a condition such as arthritis or a common characteristic such as frailty in old age It complements the traditional focus on institutions, or specialties or technologies and its aim is to maximise value for those populations and the individuals within them.
Right Care Atlas of Variation in Healthcare - Children and Young Peoplerightcare
For the first time, variations across the breadth of child health services provided by NHS England are presented together to allow clinicians, commissioners and service users to identify priority areas for improving outcome, quality and productivity.
This presentation is by Dr Ronny Cheung, Atlas editor and Paediatric SpR St Thomas' Hospital, London
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
NHS Atlas of Variation in Healthcare for People with Liver Disease
1. Key Headlines
in the NHS Atlas of
Variation for
People with Liver
Disease
Copyright 2011 Right Care
2. Introducing the Atlas of Variation in Healthcare for People
with Liver Disease
- 38 indicators mapped
- Covering topics ranging from
Transplantation, alcohol, prescribing,
and obesity, amongst other
- Produced with NHS Liver and the
Health Protection Agency
- contributions from 24 other
organisations
- 12 case studies of innovation and
good practice
- With preface from three major liver
charities
2
3. Preface
[This Atlas] will highlight gaps in prevention
initiatives and the provision of health services
and will draw attention to localities where
improvements are needed. Most importantly, it
will empower patients to ask questions about
the healthcare they receive and the options
available to them.
3
4. A key issue for population health
In the Annual Report of
the Chief Medical Officer
(CMO), Volume 1, 2011,
liver disease was
identified as one of three
key issues for population
health because it is:
“the only major cause of
mortality and morbidity
which is on the increase
in England...”
4
6. Mortality from liver disease has been increasing for the past 20 years.
During the last few years, it appears to have reached a plateau,
although it is not known whether this trend in mortality can be
reversed
6
7. The key facts
• 1993-2010: 88% rise in England in age-standardised mortality
rate from chronic liver disease
• Up to 10-20% of the population are potentially at some risk
of developing some liver damage, while 600,000-700,000
individuals actually have a significant degree of damage.
• Over 24% of the population (33% of men, 16% of women)
consume alcohol in a way that is potentially or actually
harmful
• In England, there are potentially 1.4m adults with fatty liver
disease. 26% of the adult population in England is thought to
be obese
• Up to 500,000 children may already be at risk of liver disease
because of their weight
7
8. Key Themes
• There is significant local variation in these mortality
rates, with deprivation a key factor. (Maps 1-5)
• Major evidence of alcohol abuse by children, with big
local variations in the numbers admitted to hospital for
alcohol-related problems. (Map 10)
• Unexplained variations in local prescribing patterns for
people with harmful drinking (Maps 12 & 14)
• Not all babies at risk of hepatitis B are being immunised
to protect them. (Map 17)
• Growing obesity in children is increasing the risk of
serious liver disease in later life. (Maps 28-29)
8
9. Why Variation matters…
Maps of variation in healthcare matter because they
support an understanding that different resources or
solutions may be required in different localities, but
they also serve as a powerful tool for orientation, a
comparator and a benchmark to show commissioners,
clinicians and providers where they stand among their
peers.
Maps can help to highlight localities where variation in
outcomes may require more detailed investigation or
a different solution.
9
10. Much more needs to be done at an earlier stage of liver disease to
reduce premature mortality. Indeed, the opportunities for
intervention and the effect of intervention probably diminish with
the progression of liver disease, whereas the relative costs of the
interventions that can be applied increase
10
12. Emergency Admissions
In some localities, people are twice as
likely to be admitted to hospital as an
emergency attributable to liver disease.
Reasons could include differences in:
›› the distribution of risk factors for
liver disease;
›› the prevalence of liver disease in
different populations;
›› the types and volumes of liver
disease;
›› the coding of cases.
The degree of variation observed,
however, probably includes
unwarranted variation due to
differences in the organisation and
management of care for people with
liver disease in local health services.
12
13. Chronic Liver Disease
Premature death from chronic
liver disease has been rising -
between 1993 and 2010 the
directly age-standardised
mortality rate in England
increased by 88%.
There is a 9-fold variation in rates
for PCTs. When the five PCTs with
the highest rates and the five
PCTs with the lowest rates are
excluded, the variation is 3.9-fold.
13
14. Sources of Variation
Potential reasons for the degree of variation observed
include differences in:
›› the prevalence of diabetes, obesity, hepatitis B and
hepatitis C;
›› the level of alcohol consumption;
›› the level of investment in preventative measures;
›› the configuration of services;
›› the timing of diagnosis;
›› degree of adherence to clinical guidance;
›› level of patient compliance with prevention or treatment.
14
15. Chronic Liver Disease
Cirrhosis of the liver is an important
cause of illness and death.
In 2010, it killed more people than
were killed in transport accidents and
more women than cancer of the
cervix.
The rate of people admitted to
hospital at least once for cirrhosis
varied 3.9-fold.When the five PCTs
with the highest rates and the five
PCTs with the lowest rates are
excluded, the range is 60.7–171.6 per
100,000 population, and the variation
is 2.8-fold.
15
16. Liver Cancer
Around 3,900 people every year are
diagnosed with primary liver cancer
each year in the UK, which accounts
for about 1% of all cancers in the UK.
Secondary liver cancer, spreading
from elsewhere in the body, is far
more common than primary liver
cancer.
For PCTs in England, the rate of liver
cancer mortality in people aged under
75 years ranged from 0.5 to 5.3 per
100,000 population (10-fold
variation). When the 5 PCTs with the
highest rates and the 5 PCTs with the
lowest rates are excluded, the range is
0.8–3.6 per 100,000 population, and
the variation is 4.6-fold.
16
17. Transplantation
For PCTs in England, the rate of liver
transplants from all donors ranged
from 4.5 to 28.5 per million population
(pmp) (6-fold variation)
When the five PCTs with the highest
rates and the five PCTs with the lowest
rates are excluded, the range is 6.0–
22.5 pmp, and the variation is 3.7-fold.
Potential reasons for variation include
differences in:
›› access to local expertise in liver
disease;
›› criteria for selection for
consideration for liver transplant;
›› care pathways for people who may
require a liver transplant.
17
18. Alcohol Dependency
In England, alcohol dependence affects 4% of people aged
between 16 and 64 years (6% of men and 2% of women); over
24% of the population (33% of men and 16% of women) consume
alcohol in a way that is potentially or actually harmful to their
health or well-being.
In England, of the 1 million people aged 16–64 years who are
alcohol dependent, only about 6% per year receive treatment:
›› there is often a long period between developing alcohol
dependence and seeking help;
›› there is limited availability of specialist alcohol treatment
services in some parts of the country;
›› alcohol misuse is under-identified by health and social care
professionals.
18
19. Admissions for Alcohol Use
Alcohol misuse costs the country around
£21 billion a year1. In 2011, the
Department of Health estimated the cost
to the NHS of alcohol-related harm as
£3.5 billion.
The rate of alcohol-related admissions
ranged from 1048.1 to 3557.3 per
100,000 population (3.4-fold variation).
When the 5 PCTs with the highest rates
and the 5 PCTs with the variation is
2.1-fold.
Some of the variation is likely to be due to
differences in alcohol use, although other
factors such as differences in coding for
association with alcohol could explain
some of the variation.
1. Health Committee. Written evidence from the Department of Health (GAS
01). Annex B, paragraph 2.
http://www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/1
32/132we02.htm
19
20. Admissions for Alcohol use
For PCTs in England, the rate of
alcohol-specific conditions in people
aged under 18 years ranged from 16.9
to 138.3 per 100,000 population (8-
fold variation). When the 5 PCTs with
the highest rates and the 5 PCTs with
the lowest rates are excluded, the
variation is 4.7-fold.
Much of the variation observed is likely
to be due to differences in the rate of
alcohol use. Other reasons for
variation include the level of
deprivation, which appears to have an
adverse impact, the level of obesity,
which can worsen the impact of
alcohol, demography, and coding for
association with alcohol
20
21. Hepatitis and Drug Use
People who inject drugs are at greatest risk of hepatitis C infection.
Infections are acquired when people share contaminated injecting
equipment.
Ensuring people who use drugs do not contract hepatitis is one way of
ensuring their safety and that of the local community before and during
their recovery. Preventing transmission also has benefits for civil
society by reducing:
›› harms to health;
›› treatment costs.
When people who inject drugs receive treatment for their addiction, it
provides an opportunity to undertake hepatitis C testing to identify
new cases.
21
22. Hepatitis
For PCTs in England, the percentage of
hepatitis C test uptake among people who
inject drugs receiving drug treatment
ranged from 14.8% to 87.4% (6-
fold variation).
When the five PCTs with the highest
percentages and the five PCTs with the
lowest percentages are excluded, the
range is 26.5–74.2%, and the variation is
2.8-fold.
When interpreting the magnitude of
variation, it is important to note:
›› the indicator does not include people
who do not start treatment at all and/or
who are not in touch with services;
›› some people who inject drugs are very
mobile and may present to different
services at different times.
22
23. Hepatitis
Although hepatitis C virus is a chronic
infection, antiviral treatments are available
that will successfully clear the virus in the
majority of patients. However, unless there
is a considerable increase in people
receiving effective treatment, the future
burden of hepatitis C-related disease will
be substantial.
Admission to hospital for hepatitis C and
end-stage liver disease (ESLD) is an
outcome indicator of how successful the
identification and care of people with
hepatitis C and its prevention have been.
There is an 11 fold variation in the rate of
hospital admissions for hepatitis C-related
ESLD when the five PCTs with the highest
rates and the five PCTs with the lowest
rates are excluded.
23
24. The Obesity Epidemic
In England, there are potentially 1.4 million adults with fatty liver
disease which may in some cases to lead to cirrhosis (non-alcoholic
steatohepatitis) over the long term. We also estimate that there could
be 60,000 10-year-olds with fatty liver. Extrapolating this for children
aged 5–15 years, up to 500,000 children may already be at risk of
developing an underlying liver disease that could lead to cirrhosis in the
future.
Obesity is closely related to
the development of fatty
liver disease, and 26% of the
adult population, around
14.3 million people in
England, is thought to be
obese
24
25. Obesity
For PCTs in England, the percentage
of children in school year 6 classified
as overweight or obese ranged from
24.6% to 41.8% (1.7-fold variation).
When the five PCTs with the highest
percentages and the five PCTs with
the lowest percentages are excluded,
the range is 28.8–40.3%, and the
variation is 1.4-fold.
25
26. Obesity
For PCTs in England, the
percentage of estimated adult
obesity ranged from 14.0% to
30.7% (2.2-fold variation).
When the five PCTs with the
highest estimated
percentages and the five PCTs
with the lowest estimated
percentages are excluded, the
range is 15.6–29.0%, and the
variation is 1.9-fold.
26
28. Cholecystectomy
The degree of variation observed in total
rates of cholecystectomy after exclusion is
2.4-fold whereas it is 8-fold for the
percentage of elective adult day-case
laparoscopic cholecystectomy per all
elective cholecystectomies. If total rates of
cholecystectomy are considered as a proxy
for the burden of disease, it would appear
that there is less variation in the burden of
disease when compared with the variation
in the type of care given.
Further investigation is needed into the
possible causes of lower rates of day-case
surgery.
If all providers in England were to match
the day case performance of those in the
upper quartile of day-case surgery rates for
the BADS set of procedures, the estimated
annual saving could release more than £64
million.
28
29. Endoscopic Retrograde
Cholangiopancreatography
ERCP is a procedure in which an
endoscope and X-rays are used to
visualise the bile duct and the
pancreatic duct. It can be used to
diagnose or treat various conditions
such as bile duct stones or pancreatic
cancer. There should be no reason
why the majority of patients
undergoing the intervention as an
elective procedure require an
overnight stay.
For PCTs in England, the variation is
28-fold. When the five PCTs with the
highest percentages and the five
PCTs with the lowest percentages are
excluded, the variation is 13-fold.
29
30. Endoscopic Retrograde
Cholangiopancreatography
The degree of variation observed in total rates of cholecystectomy after
exclusion is 2.4-fold (see Map 31) whereas it is 8-fold for the percentage of
elective adult
day-case laparoscopic cholecystectomy per all elective
cholecystectomies.
The degree of variation observed in total rates of ERCP procedures after
exclusion is 2.2-fold (see Map 33) whereas it is 13-fold for the percentage
of elective ERCP procedures performed as day cases.
If total rates of cholesystectomy and ERCP are considered as a proxy for
the burden of disease, it would appear that there is less variation
in the burden of disease when compared with the variation in
the type of care given. Further investigation is needed into the
possible causes of lower rates of day-case procedures.
30
31. Reasons for variation
The degree of variation observed in total rates of cholecystectomy
after exclusion is 2.4-fold (see Map 31) whereas it is 8-fold for the
percentage of elective adult day-case laparoscopic cholecystectomy
per all elective cholecystectomies.
The degree of variation observed in total rates of ERCP procedures
after exclusion is 2.2-fold (see Map 33) whereas it is 13-fold for the
percentage of elective ERCP procedures performed as day cases.
If total rates of cholecystectomy and ERCP are considered as a proxy
for the burden of disease, it would appear that there is less variation
in the burden of disease when compared with the variation in
the type of care given.
Further investigation is needed into the possible causes of lower
rates of day-case procedures.
31
32. Innovations and models of good practice in services
While working on the National Liver Disease Strategy, many models of good
practice and some innovations likely to be helpful in tackling unwarranted
variation were identified (Figure CS.1). They are presented in this Atlas as
exemplars so that commissioners, clinicians and service providers can
consider how they may be applied in their locality.
32
33. Identifying liver disease earlier
Risk assessment and early recognition of liver disease has been promoted
by Liverpool PCT-CCG through the use of a locally enhanced service payment
to minimise late diagnosis.
Incentives are available to all participating primary care groups who:
›› identify patients at risk;
›› undertake relevant blood tests;
›› refer only those patients who meet the criteria for referral that have been
agreed with local secondary care services – other patients are managed
entirely in the community
It was found that practices had different criteria and standards for referral within
the PCT. Referral criteria and information standards were agreed with
secondary care providers who agreed to provide a consultant-level opinion.
Up to 40% of patients can be discharged with an advisory care plan at first
consultation.
33
34. Nottingham
A variation of this type of service model was developed in
Nottingham where all CCG referrals from individual practices were
centralised at a single practice.
A two-level triage system was used, in which a general practitioner
with an interest in gastroenterology screened referrals. In cases
where there was uncertainty, a brief synopsis of the case was
emailed to 1 of 5 consultant hepatologists/gastroenterologists who
screened the scenario and made clinical recommendations.
Of a total of 354 potential referrals screened using this system during
one year, 75% of hepatology referrals were dealt with by giving
advice, blood tests, recommendations and appropriate community
management plans.
34
35. Alcohol abuse - Delivering brief interventions
The introduction of alcohol liaison nurses has been recommended by
the British Society of Gastroenterology and accepted by NHS
Evidence as a QIPP example.
In Nottingham, the introduction of an alcohol liaison nurse reduced
readmission rates and drinking rates during a 12-month follow-up
period.
Similar models have proved effective in Bolton and Liverpool.
In Salford, an extension of this process has been used to identify
frequent attendees at A&E who are also known to other local
authority agencies: a coordinated approach with key workers has
decreased attendances and readmission rates.
35
36. Triage of patients to secondary care…
In Southampton, an algorithm was developed to triage patients to no fibrosis
(green), cirrhosis (red), or an in-between group (amber) to whom
interventions could be targeted to impede progression of scarring disease in
the liver.
Three tests were used - hyaluronic acid, collagen P3 peptide, and platelet
count
Ten thousand people in primary care were contacted by their own GPs and
had their alcohol intake assessed:
›› just over 30% were assigned to the green category of
risk of liver disease;
›› just over 40% were assigned to the amber category
of risk of liver disease;
›› just under 30% were assigned to the red category of
risk of liver disease.
36
37. …Triage of patients to secondary care
After assessment at one year, it was found that the initial categorisation was
accurate with respect to not only the proportion of people assigned to each
category of risk but also the severity of liver disease attributed to each
individual.
By identifying people in each category, preliminary results suggest that the
higher the risk category identified, the greater is the impact of interventions
aimed at reducing alcohol consumption in each group. This and other
evidence points to the importance of individualising the information and risk
assessment for people at risk of liver disease.
37
38. Patient involvement: shared decision-making…
Involvement of patients in the decision-making process leads to higher
satisfaction, improved outcomes, greater knowledge of their condition and
increased adherence to treatments.
At University Hospitals Birmingham, patients were provided with the tools to
engage in the decision making process, including access to their own health
records, the ability to communicate with patients who have similar conditions
and access to appropriate healthcare resources.
A shadow hospital IT system was created that included the electronic
prescribing and electronic outpatient note-keeping systems, so that patients
could view their letters, appointments and blood-test results. As well as
being able to access their health records, patients can also communicate
with their healthcare team and learn about their long-term condition and its
management.
38
39. … Patient involvement: shared decision-making
After successful feedback about the pilot, the system went live in July 2012
to patients being treated within the entire liver medicine specialty and also 10
other specialities within the Trust.
After this initial rollout phase, there will be an external evaluation of the
project. This is the first such project for patients with liver disease, although
patients with kidney disease have experienced the benefits of a similar
system, known as Renal PatientView4, for many years1.
1.http://www.renalpatientview.org
39
40. www.rightcare.nhs.uk/atlas
In print
You can order free printed copies
using the online form on our website
Online
High and Low resolution PDFs are
available for download
Interactive
A fully interactive InstantAtlastm
is available online
40
41. Follow Right Care online:
- Subscribe to get a weekly digest of our blog in your inbox
- Receive Occasional eBulletins
- Follow us on Twitter @qipprightcare
www.rightcare.nhs.uk
41